ABOS•benzinga•March 19, 2025 at 12:08 PM

Acumen Pharmaceuticals Announces Topline Results From Phase 1 Study Of Subcutaneous Formulation Of Sabirnetug In Healthy Volunteers; Weekly Subcutaneous Administration Of Sabirnetug Was Well-Tolerated In The Phase 1 Study

No summary available.

Read the full article from the original source for complete details and context.

Article published on March 19, 2025 by benzinga